Your browser doesn't support javascript.
loading
Evaluating the Impact of Applying Personal Glucose Targets in a Closed-Loop System for People With Type 1 Diabetes.
Fattah, Mustafa; Boughton, Charlotte K; Ware, Julia; Allen, Janet M; Hartnell, Sara; Willinska, Malgorzata E; Thankamony, Ajay; de Beaufort, Carine; Campbell, Fiona M; Fröhlich-Reiterer, Elke; Hofer, Sabine E; Kapellen, Thomas M; Rami-Merhar, Birgit; Ghatak, Atrayee; Randell, Tabitha L; Besser, Rachel E J; Elleri, Daniela; Trevelyan, Nicola; Denvir Md, Louise; Davis, Nikki; Bally, Lia; Thabit, Hood; Leelarathna, Lalantha; Evans, Mark L; Mader, Julia K; Hovorka, Roman.
Affiliation
  • Fattah M; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Boughton CK; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Ware J; Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Allen JM; University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.
  • Hartnell S; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Willinska ME; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Thankamony A; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • de Beaufort C; Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Campbell FM; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Fröhlich-Reiterer E; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Hofer SE; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Kapellen TM; Diabetes & Endocrine Care Clinique Pediatrique, Pediatric Clinic/Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
  • Rami-Merhar B; Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-Belval, Luxembourg.
  • Ghatak A; Department of Paediatric Diabetes, Leeds Children's Hospital, Leeds, UK.
  • Randell TL; Department of Pediatrics, Medical University of Graz, Graz, Austria.
  • Besser REJ; Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.
  • Elleri D; Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany.
  • Trevelyan N; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Denvir Md L; Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
  • Davis N; Nottingham Children's Hospital, Nottingham, UK.
  • Bally L; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Thabit H; NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
  • Leelarathna L; Royal Hospital for Children & Young People, Edinburgh, UK.
  • Evans ML; Southampton Children's Hospital, Southampton, UK.
  • Mader JK; Nottingham Children's Hospital, Nottingham, UK.
  • Hovorka R; Southampton Children's Hospital, Southampton, UK.
J Diabetes Sci Technol ; : 19322968221145184, 2022 Dec 20.
Article in En | MEDLINE | ID: mdl-36540007
ABSTRACT

BACKGROUND:

CamAPS FX is a hybrid closed-loop smartphone app used to manage type one diabetes. The closed-loop algorithm has a default target glucose of 5.8 mmol/L (104.5 mg/dL), but users can select personal glucose targets (adjustable between 4.4 mmol/L and 11.0 mmol/L [79 mg/dL and 198 mg/dL, respectively]).

METHOD:

In this post-hoc analysis, we evaluated the impact of personal glucose targets on glycemic control using data from participants in five randomized controlled trials.

RESULTS:

Personal glucose targets were widely used, with 20.3% of all days in the data set having a target outside the default target bin (5.5-6.0 mmol/L [99-108 mg/dL]). Personal glucose targets >6.5 mmol/L (117 mg/dL) were associated with significantly less time in target range (3.9-10.0 mmol/L [70-180 mg/dL]; 6.5-7.0 mmol/L [117-126 mg/dL] mean difference = -3.2 percentage points [95% CI -5.3 to -1.2; P < .001]; 7.0-7.5 mmol/L [126-135 mg/dL] -10.8 percentage points [95% CI -14.1 to -7.6; P < .001]). Personal targets >6.5 mmol/L (117 mg/dL) were associated with significantly lower time (<3.9 mmol/L [<70 mg/dL]; 6.5-7.0 mmol/L [117-126 mg/dL] -1.85 percentage points [95% CI -2.37 to -1.34; P < .001]; 7.0-7.5 mmol/L [126-135 mg/dL] -2.68 percentage points [95% CI -3.49 to -1.86; P < .001]).

CONCLUSIONS:

Discrete study populations showed differences in glucose control when applying similar personal targets.
Key words

Full text: 1 Database: MEDLINE Type of study: Clinical_trials Language: En Journal: J Diabetes Sci Technol Journal subject: ENDOCRINOLOGIA Year: 2022 Type: Article Affiliation country: United kingdom

Full text: 1 Database: MEDLINE Type of study: Clinical_trials Language: En Journal: J Diabetes Sci Technol Journal subject: ENDOCRINOLOGIA Year: 2022 Type: Article Affiliation country: United kingdom